Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.54 USD
Change Today -0.0049 / -0.90%
Volume 210.9K
DCTH On Other Exchanges
Symbol
Exchange
DCTH is not on other exchanges.
As of 3:29 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

delcath systems inc (DCTH) Snapshot

Open
$0.55
Previous Close
$0.55
Day High
$0.58
Day Low
$0.52
52 Week High
09/15/14 - $2.78
52 Week Low
07/22/15 - $0.46
Market Cap
11.7M
Average Volume 10 Days
938.7K
EPS TTM
$-1.35
Shares Outstanding
21.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DELCATH SYSTEMS INC (DCTH)

delcath systems inc (DCTH) Related Businessweek News

No Related Businessweek News Found

delcath systems inc (DCTH) Details

Delcath Systems, Inc. operates as a specialty pharmaceutical and medical device company focusing on cancers of the liver. The company is developing its proprietary product-Melphalan Hydrochloride for injection for use with the Delcath Hepatic Delivery System; and markets melphalan hydrochloride as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan in Europe. Its primary focus is on the execution of its clinical development program in ocular melanoma liver metastases, intrahepatic cholangiocarncinoma, hepatocellular carcinoma, and certain other cancers that are metastatic to the liver. Delcath Systems, Inc. was founded in 1988 and is headquartered in New York, New York.

25 Employees
Last Reported Date: 03/11/15
Founded in 1988

delcath systems inc (DCTH) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: $401.3K
Executive Chairman
Total Annual Compensation: $40.0K
Principal Financial Officer, Principal Accoun...
Total Annual Compensation: $233.1K
Executive Vice President of Regulatory Affair...
Total Annual Compensation: $284.3K
Compensation as of Fiscal Year 2014.

delcath systems inc (DCTH) Key Developments

Delcath Receives Orphan Drug Designation from FDA for Melphalan to Treat Cholangiocarcinoma

Delcath Systems, Inc. announced that the U.S. Food and Drug Administration(FDA) Office of Orphan Products Development (OOPD) has granted Orphan Drug Designation for melphalan for the treatment of cholangiocarcinoma. The OOPD is tasked with evaluating the scientific and clinical data submissions from sponsors to identify and designate products as promising for rare diseases and to further advance scientific development of such promising medical products. Intrahepatic cholangiocarcinoma (ICC), a sub-category of cholangiocarcinoma, is a tumor in the bile duct that arises within the liver. It is the second most common primary liver tumor and represents approximately 15% of new HCC cases diagnosed annually. Surgical resection, the standard of care, is not possible for an estimated 80% to 90% of patients diagnosed with ICC. The Company recently announced the expansion of its global Phase 2 clinical study in primary liver cancer (HCC) to include an ICC cohort, which is investigating the safety and efficacy of Melphalan/HDS treatment in patients with unresectable ICC confined to the liver. The study is being conducted at the same hospitals in Europe participating in the Company's Phase 2 HCC trial, and is expected to enroll 11 patients. The ICC cohort will evaluate tumor response (objective response rate) as measured by modified Response Evaluation Criteria in Solid Tumor (mRECIST), and will assess progression-free survival and safety. Additional analyses will be conducted to characterize the systemic exposure of melphalan administered by Melphalan/HDS, as well as to assess patient-reported clinical outcomes, or quality-of-life.

Delcath Systems, Inc. Approves the Appointment of Grant Thornton, LLP as Independent Registered Public Accounting Firm for the Year Ending December 31, 2015

Delcath Systems, Inc. approved the appointment of Grant Thornton, LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2015 at its AGM held on June 10, 2015.

Delcath Systems, Inc. - Shareholder/Analyst Call

Annual Meeting of Shareholders

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DCTH:US $0.54 USD -0.0049

DCTH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AngioDynamics Inc $15.49 USD +0.28
CTI BioPharma Corp $1.84 USD -0.005
Curis Inc $3.13 USD -0.07
Exact Sciences Corp $23.99 USD -0.2299
Sirtex Medical Ltd A$30.84 AUD +0.47
View Industry Companies
 

Industry Analysis

DCTH

Industry Average

Valuation DCTH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.9x
Price/Book 0.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DELCATH SYSTEMS INC, please visit www.delcath.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.